PIK3CA mutations, phosphatase and tensin homolog, human epidermal growth factor receptor 2, and insulin-like growth factor 1 receptor and adjuvant tamoxifen resistance in postmenopausal breast cancer patients
about
Triple negative breast cancer: looking for the missing link between biology and treatmentsPI3K mutations in breast cancer: prognostic and therapeutic implicationsLoss of PTEN expression in breast cancer: association with clinicopathological characteristics and prognosis.Prognostic role of PIK3CA mutations and their association with hormone receptor expression in breast cancer: a meta-analysis.Denoising perturbation signatures reveal an actionable AKT-signaling gene module underlying a poor clinical outcome in endocrine-treated ER+ breast cancer.Significance of PIK3CA Mutations in Patients with Early Breast Cancer Treated with Adjuvant Chemotherapy: A Hellenic Cooperative Oncology Group (HeCOG) Study.Activation of PI3K/Akt/mTOR signaling in the tumor stroma drives endocrine therapy-dependent breast tumor regression.Rationale-based therapeutic combinations with PI3K inhibitors in cancer treatmentProteins Involved in HER2 Signalling Pathway, Their Relations and Influence on Metastasis-Free Survival in HER2-Positive Breast Cancer Patients Treated with Trastuzumab in Adjuvant SettingPhosphorylated p-70S6K predicts tamoxifen resistance in postmenopausal breast cancer patients randomized between adjuvant tamoxifen versus no systemic treatment.The use of 18F-Fluoro-deoxy-glucose positron emission tomography (18F-FDG PET) as a non-invasive pharmacodynamic biomarker to determine the minimally pharmacologically active dose of AZD8835, a novel PI3Kα inhibitor.Enrichment of PI3K-AKT-mTOR Pathway Activation in Hepatic Metastases from Breast Cancer.BRCA1-like signature in triple negative breast cancer: Molecular and clinical characterization reveals subgroups with therapeutic potentialIncreased MAPK1/3 Phosphorylation in Luminal Breast Cancer Related with PIK3CA Hotspot Mutations and Prognosis.Loss of protein tyrosine phosphatase, non-receptor type 2 is associated with activation of AKT and tamoxifen resistance in breast cancer.Endocrine therapy: defining the path of least resistance.Hyperactive mTOR and MNK1 phosphorylation of eIF4E confer tamoxifen resistance and estrogen independence through selective mRNA translation reprogramming.Mechanism of resistance to endocrine therapy in breast cancer: the important role of PI3K/Akt/mTOR in estrogen receptor-positive, HER2-negative breast cancer.Predicting and Overcoming Chemotherapeutic Resistance in Breast Cancer.Prognostic and histogenetic roles of gene alteration and the expression of key potentially actionable targets in salivary duct carcinomas.Characterization of PIK3CA and PIK3R1 somatic mutations in Chinese breast cancer patients.E-cadherin loss induces targetable autocrine activation of growth factor signalling in lobular breast cancer
P2860
Q26783122-4BBCE597-6F48-4778-AE9F-EC3733C4D7A7Q28081992-B77D2D48-F621-4395-87FA-9E350F0A5B60Q33762003-EF82A9B4-F7CC-42ED-BD13-184E20D16C3AQ34112879-74B7AE7E-D2F8-47F2-B4C1-7A53936C8FF3Q35446364-59640189-40E4-4FBD-9ED2-5BDDEBA9F04AQ35801713-24E2777F-1190-4EBD-86A0-43F3CD7DCF01Q36355880-510A9B2A-C3AF-41EF-A900-9975E78138B6Q36997524-94C47E23-F20A-47DF-AB61-C149D70E94A1Q37604329-76E3F22C-0320-48B6-A542-FAC848492310Q37691173-51A3B3F3-7BF3-4595-BF2F-2800CC3AD53BQ38625610-5AEF4C83-0D60-41F1-899C-FDD94A04923FQ38818107-D544CA68-889A-4C78-B1F6-D86608B644DAQ40907759-4FB74ADA-E964-4FC5-A131-46140E610952Q41472845-73AA2FAC-A2D9-44B8-A077-59980649A91CQ41550474-1119AAF3-AF2D-4D1C-9D38-BD9384D89F2BQ42670599-2AE2EAE5-5D4D-4AEE-8847-534AC30FC837Q47263046-64BA8BDC-6FE9-46E7-95B0-CD9185DC7823Q47584016-08A55DDD-87BE-43EF-B7B5-D03EA88479DCQ49544395-E714149F-FD88-4FF3-A070-62F8AAA6DCA7Q49688722-D25D7580-D619-4438-B96D-E7B6DCF1AB36Q52595390-D3AB87F8-DF0B-4C87-878E-26AB036501DEQ58603744-11363F95-7AFA-484C-8735-9E189CCE3CF9
P2860
PIK3CA mutations, phosphatase and tensin homolog, human epidermal growth factor receptor 2, and insulin-like growth factor 1 receptor and adjuvant tamoxifen resistance in postmenopausal breast cancer patients
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 27 January 2014
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
PIK3CA mutations, phosphatase ...... opausal breast cancer patients
@en
PIK3CA mutations, phosphatase ...... pausal breast cancer patients.
@nl
type
label
PIK3CA mutations, phosphatase ...... opausal breast cancer patients
@en
PIK3CA mutations, phosphatase ...... pausal breast cancer patients.
@nl
prefLabel
PIK3CA mutations, phosphatase ...... opausal breast cancer patients
@en
PIK3CA mutations, phosphatase ...... pausal breast cancer patients.
@nl
P2093
P2860
P356
P1476
PIK3CA mutations, phosphatase ...... opausal breast cancer patients
@en
P2093
Andrew D Vincent
Els M J J Berns
Jan B Vermorken
Jelle Wesseling
Jettie J Muris
Karin Beelen
Mark Opdam
Paul J van Diest
Rutger H T Koornstra
Sabine C Linn
P2860
P2888
P356
10.1186/BCR3606
P577
2014-01-27T00:00:00Z
P5875
P6179
1052835846